The compounds, which prevent the abnormal aggregation of the TTR protein, work by holding the protein together in its functional form. These compounds have the potential one day to help the hundreds of thousands of people who have TTR-related amyloid diseases or are at risk for them, and may have advantages over other TTR-stabilizing drugs, which are currently in clinical trials.
"These new compounds have structures that make them very effective at stabilizing TTR in its stable native tetrameric form in laboratory tests, and they also seem nontoxic in cell culture," said Stephen Connelly, a senior research associate in the Scripps Research laboratory of Professor Ian Wilson.
Connelly, who determined the molecular structures of these TTR-stabilizing compounds, is a co-lead-author of the report, which appears in the current issue of Science Translational Medicine. The other lead author is Mamoun M. Alhamadsheh, who at the time of the study was a postdoctoral researcher in the laboratory of Isabella Graef, an assistant professor of pathology at Stanford University.
Defenses against Abnormal Forms
TTR proteins normally don't work alone. Single "monomeric" copies come together in pairs, and then in pairs of these pairs, to form four-protein structures known as "tetramers." Secreted by the liver into the bloodstream, TTR tetramers work as transporters of the hormone thyroxine and also bind the holo retinal binding protein. In the hustle and bustle of the bloodstream, however, TTR tetramers often come apart, and when that happens, the naturally sticky individual TTR proteins may start to re-form abnormally, into toxic fibril-shaped aggregates known as amyloids.
"It's well known that the body's normal defenses against amyloids decline with aging," said Graef. Apparently for that reason, TTR amyloids are found at autopsy in the heart and other organs of 10 to 15 percent of people over 65, although they almost never accumulate in young people.
TTR amyloids don't always cause symptoms, but in many cases they do impair functions or hasten age-related degeneration. Inherited mutations of the TTR gene can cause earlier-onset TTR amyloid conditions, including familial amyloid cardiomyopathy, which often causes heart failure and is particularly common in West Africans and African-Americans.
First-generation drug candidates for preventing TTR amyloid formation have been developed, and two are already in clinical trials. But most of these have chemical similarities to non-steroidal anti-inflammatory drugs (NSAIDs). As such, they have potentially harmful side effects—including to the heart and kidney—that would make them less than ideal for long-term use, especially in patients with compromised heart function. Graef and her colleagues therefore developed an innovative and novel test to screen a library of compounds for those that would bind and stabilize TTR but otherwise would not have NSAID-like effects.
They found 33 powerful TTR stabilizers with their screening system. "Many of these were novel chemical entities with no previously known biological targets," Graef said. After selecting the most potent of the compounds—some of which seemed even more potent than those in clinical trials—she and her team used further lab tests to confirm the compounds' effectiveness at preventing amyloid formation by normal and mutant forms of TTR. Preliminary tests of the compounds' toxicity also showed that they did not appear to harm normal cells.
Strengthening Weaker Joints
Often when scientists find a promising drug candidate in initial screens, they try to determine the precise molecular shape it makes in conjunction with its target. With this information, they can modify it chemically, for example to make it bind to the target more tightly and exclusively. Thus Graef brought four of her best TTR-stabilizing compounds to Scripps Research for structural analysis. "We have one of the world's largest and most advanced facilities for determining protein structures, and we've done this for almost 30 TTR-drug complexes to date" Connelly said.
Using cutting-edge X-ray crystallography techniques, Connelly soon solved the structures of the four compounds as they bound to TTR. "Despite their diverse chemical differences, all four turned out to bind to the TTR tetramer in ways that span and thereby strengthen its weaker joints, stabilizing the healthy tetrameric form," said Connelly.
Graef and her colleagues at Stanford now are trying to gather more data on the effectiveness and safety of the more promising compounds. "Together with physicians from a cardiovascular clinic here at Stanford, we're investigating whether these compounds can stabilize, in a solution of blood serum, the TTR proteins of patients with a common familial amyloid cardiomyopathy mutation," she said. "If it can, then hopefully the pharmaceutical industry will want to develop it from there."
Others who contributed to the paper, "Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity," are Ahryon Cho and Dorothy Pan of Stanford and Natàlia Reixach and Evan Powers of Scripps Research, as well as Scripps Research Professor Jeffery Kelly, a pioneer in the development of drugs to stabilize TTR and other amyloid-prone proteins. For more information, see http://stm.sciencemag.org/content/3/97/97ra81.abstract .
This work was supported by the Hillblom Foundation, National Institutes of Health (NIH), American Heart Association, and the Skaggs Institute of Chemical Biology.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation.
Mika Ono | EurekAlert!
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy